26 June 2020
US-based biotech firm Avalon GloboCare has collaborated with the University of Natural Resources and Life Sciences (BOKU) in Vienna, Austria, to develop an S-layer vaccine against Covid-19 for intranasal or oral administration. The partners are working to develop a vaccine candidate that would trigger an immune response sufficient to prevent a severe form of Covid-19 infection.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended the conditional marketing authorisation of Gilead Sciences’ remdesivir under the brand name Veklury for Covid-19 patients aged 12 years and above with pneumonia who require supplemental oxygen. The drug is the first Covid-19 medicine to be recommended for authorisation in the European Union (EU).
The Federal University of Sao Paulo (Unifesp), Brazil is in discussions to assess a Covid-19 vaccine candidate developed by Italian researchers at Lazzaro Spallanzani National Institute, as reported by Reuters. The Italian researchers intend to perform mid-stage and final Phase III trials in Brazil.
Theravance Biopharma has dosed first patient in the Phase II clinical trial of TD-0903 to treat hospitalised patients with acute lung injury (ALI) caused by Covid-19 infection. TD-0903 is believed to be able to block the cytokine storm related to ALI and prevent progression to acute respiratory distress syndrome (ARDS).
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
